Biotech has a peculiar rhythm. The science moves in bursts, the funding arrives in waves, and the stakes stay high the whole time. A lab result can feel definitive on Tuesday and become a question mark by Friday once the next dataset arrives. Scaling, in that environment, is not only about hiring more people or raising more money. It is about building a decision system that stays coherent as uncertainty grows.
Leen Kawas has built much of her career inside that uncertainty. She is CEO of EIT Pharma and a co-founder and Managing General Partner of Propel Bio Partners, a biotech-focused fund investing in early-stage life science innovation. She also serves on the board of directors of Inherent Biosciences. Earlier, she co-founded Athira Pharma, advanced late-stage clinical programs, and led the company through its 2020 IPO while raising more than $400 million, a milestone that places her among a small group of women founders who have taken companies public.
If you track those roles, a theme emerges: governance is the bridge between scientific ambition and an institution that can carry it.
Governance begins as soon as the story leaves the lab
Early biotech can run on momentum. A handful of people share context, decisions happen quickly, and the mission feels self-evident. Scaling breaks that intimacy. New hires arrive with partial information. Partners ask for clarity. Investors ask for evidence and timing. Regulators ask for rigor. When the circle widens, the company needs a way to decide that does not rely on one person being in every conversation.
Kawas’ work spans operating a company, investing in companies, and serving as a director. That blend tends to sharpen a leader’s attention to governance as a practical tool. Governance is how you preserve scientific integrity while still moving at commercial speed. It is how you keep the plot of the company intact when the cast expands.
A board is not a trophy, it is a pressure-management system
In biotech, the board’s job is often misunderstood. It is not there to generate ideas. It is there to hold a company steady through decision points that feel consequential and irreversible.
Clinical development is a chain of such points: trial design, endpoints, statistical plans, safety monitoring, and the choices around when to scale manufacturing or expand indications. A good board helps management see the tradeoffs clearly, and it insists on documentation that survives scrutiny later.
Kawas’ board role at Inherent Biosciences signals her comfort operating at that oversight layer, bringing experience across discovery, clinical development, regulatory strategy, and financing. Her venture role adds another perspective: investors do not only back science, they back governance. A company that cannot make clean decisions under pressure becomes expensive to fund and difficult to partner with.
Scaling requires guardrails that protect the science
The fastest-growing teams are often the ones most at risk of self-deception. When capital is available and timelines feel urgent, there is a temptation to move faster than the evidence supports. Governance is the antidote, provided it is designed well.
In Leen Kawas’ case, her experience leading Athira through late-stage work and into a public offering suggests a strong emphasis on systems that keep development disciplined while still enabling progress. Going public increases the number of stakeholders dramatically. That change forces process: clearer reporting, clearer risk disclosure, and stronger internal controls.
A governance-focused leader internalizes that lesson early: build the reporting muscle before you are forced to. Build the clinical decision logs before the questions arrive. Build the culture where someone can say, “This result is interesting, and it is not enough yet,” without being punished for slowing momentum.
The CEO’s real job is accountability architecture
Biotech CEOs are often described as visionaries. The more useful description is architect. The CEO designs who owns which decisions, what happens when data conflicts, and how dissent is handled. That is governance in motion.
EIT Pharma’s profile emphasizes Kawas as an executive who operates at the intersection of science, investment, and leadership. From a governance lens, that intersection matters. It means she is positioned to translate between scientific teams, capital providers, and external stakeholders who need different kinds of certainty.
In practice, this is what scaling looks like: making sure the company can answer questions with the same clarity at 30 people and at 300 people. The answers can evolve. The decision method should stay legible.
Venture governance is upstream governance
Propel Bio Partners adds a further dimension. Investing puts you close to pattern recognition. You see which early choices create later fragility: overly concentrated decision-making, vague roles, weak documentation, a culture that treats questions as disloyalty. You also see what creates durability: strong governance that still feels lightweight.
Kawas’ role at Propel is framed around backing emerging innovators with capital and expertise, informed by her experience as a scientist and operator. That kind of fund can influence governance upstream by encouraging founders to build boards thoughtfully, formalize advisory structures, and set expectations for how scientific decisions will be reviewed.
This is where governance becomes a scaling multiplier. It prevents the “rebuild the plane mid-flight” problem later, when clinical programs are expensive and timelines are less forgiving.
A practical takeaway
Kawas’ career arc suggests a grounded view: biotech scales when governance scales with it. Capital matters. Science matters. Governance is what keeps capital and science aligned as complexity rises.
It is easy to treat governance as paperwork that follows success. Her path implies the reverse. Governance is part of how you earn the right to scale.
Learn more about Leen Kawas at the link below: